sterna biologicals reports phase 2a study data demonstrating efficacy of its gata 3 specific dnazyme formulation sb012 in patients with ulcerative colitis
Marburg, Germany, February 19, 2018
- Data presented at the 13th Congress of ECCO (European Crohn's and Colitis Organisation).
- SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis. This represents a further validation of GATA-3-antagonism for the treatment of a variety of chronic inflammatory diseases.
sterna biologicals GmbH & Co. KG ("sterna"), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that positive data from the SECURE study (NCT 02129439), a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with its GATA-3 specific DNAzyme formulation SB012, were presented at the 13th Congress of ECCO (European Crohn's and Colitis Organisation).